Heparanase中和肝素和低分子量肝素的抗凝属性。

文章的细节

引用

复制到剪贴板

纳赛尔新泽西,Sarig G,布兰诺B,一举一动E, Goldshmidt O, Zcharia E,李JP, Vlodavsky我

Heparanase中和肝素和低分子量肝素的抗凝属性。

J Thromb Haemost。2006年3月,4 (3):560 - 5。

PubMed ID

16460439 (在PubMed

]

文摘

背景:Heparanase是哺乳动物endo-D-glucuronidase劈开硫酸乙酰肝素(HS)细胞外基质和细胞表面。这是优先表达的免疫细胞和肿瘤细胞。Heparanase超表达在实验提高了血管生成和转移的肿瘤模型。肝素和低分了体重肝素(LMWH)抑制HS heparanase降解。摘要目的:探讨是否heparanase劈开肝素和LMWH,并阐明其影响血液凝固。方法:肝素和LMWH和重组heparanase孵化并受测量的分子大小(尺寸排阻色谱法)和抗凝活性(等离子体APTT-activated血栓形成质,和anti-Xa活动)。APTT也以血浆样品的转基因老鼠overexpressing heparanase,相比,控制老鼠。结果:肝素和LMWH的孵化heparanase导致降解基质,所显示的分子量明显降低。这是与明显抑制肝素的抗凝血活性和LMWH,显示对APTT和anti-Xa活动下降影响,分别在人血浆补充道。转基因小鼠overexpressing heparanase表现出明显短APTT比控制老鼠。 CONCLUSION: Heparanase is capable of degrading heparin and LMWH, so that its overexpression by tumor cells may contribute to heparin resistance, commonly occurring in cancer patients. In view of the complexity of the currently available heparanase activity assays, we propose an indirect approach to quantify heparanase activity by measuring the decrease in plasma APTT or anti-Xa activity exerted by the enzyme under the defined conditions.

beplay体育安全吗DrugBank数据引用了这篇文章

药物酶

药物	酶	类	生物	药理作用	行动
肝素钠	Heparanase	蛋白质	人类	未知的	底物	细节